Discovery of SARS-CoV-2 antiviral drugs through large-scale compound repurposing | Nature
Efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis (MS-SMART): a phase 2b, multiarm, double-blind, randomised placebo-controlled trial - The Lancet Neurology
Bharathy Prabaharan - Data Administrator - GP Practice | LinkedIn
Evaluating drug targets through human loss-of-function genetic variation | Nature
Queen Mary University of London has joined the Frontiers – JISC national open access deal. – Science & research news | Frontiers
Clinical Drug Development – Distance Learning | Queen Mary University of London | Masters Compare
Study at Queen Mary University of London | Leverage Edu
Frontiers | A Review of Current In Silico Methods for Repositioning Drugs and Chemical Compounds | Oncology
Research degrees - Queen Mary University of London
Study at Queen Mary University of London | Leverage Edu
Queen Mary University of London
Pharmacology and Innovative Therapeutics - Queen Mary University of London
Bharathy Prabaharan - Data Administrator - GP Practice | LinkedIn
A framework for the development of effective anti-metastatic agents | Nature Reviews Clinical Oncology
Study medicine - Queen Mary University of London
Selected Abstracts from Pharmacology 2020 - 2021 - British Journal of Clinical Pharmacology - Wiley Online Library
William Harvey Research Institute (@QMULWHRI) / Twitter
Frontiers | Review of Clinical Trials of COVID-19 Vaccination Booster in SARS-CoV-2 Variants Era: To Take It or Not To Take It | Drug Discovery
MSc/PGDip in Clinical Drug Development | William Harvey Research Institute, Queen Mary University of London
Queen Mary opens Organs-on-Chips Centre for advancements in medical research and drug development: QMUL School of Engineering and Materials Science
HKU Clinical Trials Centre
Home - 12th Clinical Biomarkers & CDx Europe 2022
